Results 31 to 40 of about 48,129 (210)

Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII

Clinical and Applied Thrombosis/Hemostasis, 2023
In 2018, Refacto AF R , a B-domain-deleted third-generation FVIII concentrate, became our preferential product. After the introduction, the development of inhibitors was prospectively monitored; retrospectively, we sought for risk factors in the patients
Louise H Hooimeijer MD, Marjet A Stein-Wit MD, Marja AJ Voskuilen RN, Michaël V Lukens PhD, Karina Meijer MD, PhD, Anja BU Mäkelburg MD, PhD, Rienk YJ Tamminga MD, PhD   +6 more
doaj   +1 more source

Perioperative blood loss during joint replacement: comparison between patients with and without hemophilia

Journal of Orthopaedic Surgery and Research, 2022
Background Although arthroplasty provides satisfactory pain relief, functional improvement, and reduced flexion contracture in patients with hemophilia arthropathy, bleeding remains the primary problem associated with hemophilic arthropathy joint ...
Shanyou Yuan, Lixia Song, Haoli Jiang, Jinghua Wang, Xianjia Ning, Wenxue Jiang   +5 more
doaj   +1 more source

Managing Relevant Clinical Conditions of Hemophilia A/B Patients

Hematology Reports, 2023
The Medical Directors of nine Italian Hemophilia Centers reviewed and discussed the key issues concerning the replacement therapy of hemophilia patients during a one-day consensus conference held in Rome one year ago. Particular attention was paid to the
Massimo Morfini, Jacopo Agnelli Giacchiello, Erminia Baldacci, Christian Carulli, Giancarlo Castaman, Anna Chiara Giuffrida, Giuseppe Malcangi, Angiola Rocino, Sergio Siragusa, Ezio Zanon   +9 more
doaj   +1 more source

Importance of Inhibitor Surveillance During Emicizumab Prophylaxis in Young Children With Hemophilia: An Illustrative Case Series

Case Reports in Hematology
Hemophilia is an X-linked inherited bleeding disorder associated with bleeding, which starts in infancy. The age of initiation of prophylaxis with clotting factor concentrate is limited by the intravenous mode of administration. Emicizumab, a Factor VIII
Kelly A. Bush, Marc Durocher, Jacqueline Limjoco, Courtney D. Thornburg   +3 more
doaj   +1 more source

HAEMOcare: The First International Epidemiological Study Measuring Burden of Hemophilia in Developing Countries

TH Open, 2019
Introduction Optimizing hemophilia care remains challenging in developing countries. Burden-of-disease studies are important to develop strategies for improving hemophilia care.
Naresh Gupta, Abderrahmane Benbouzid, Meriem Belhani, Mohammed El Andaloussi, Khadija Maani, Yasser Wali, Soraya Benchikh El Fegoun, Hossam Ali Saad, Johnny Mahlangu   +8 more
doaj   +1 more source

Factor VIII inhibitors demonstrate type I or type II kinetics in high‐titre alloantibodies and autoantibodies

Clinical and Translational Discovery
Background In the past, most references have indicated that inhibitors in inherited haemophilia A (HA) patients had type I reaction kinetics, while inhibitors in acquired haemophilia A (AHA) had type II reaction kinetics.
Cuicui Qiao, Jie Wang, Tiantian Wang, Hehe Wang, Yingfang Pan, Wei Liu, Yan Cheng, Feng Xue, Man‐Chiu Poon, Xinsheng Zhang, Yunhai Fang   +10 more
doaj   +1 more source

The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B

Blood Advances, 2018
: Data are needed on minimal factor activity (FA) levels required to prevent bleeding in hemophilia. We aimed to evaluate associations between hemophilia type and FA level and joint bleeding and orthopedic procedures using longitudinal data.
J. Michael Soucie, Paul E. Monahan, Roshni Kulkarni, Barbara A. Konkle, Marshall A. Mazepa   +4 more
doaj   +1 more source

Prophylaxis in hemophilia [PDF]

, 2023
Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B).
Catelli, Dayenne Helena, Weber, Cristiane Seganfredo, Silla, Lucia Mariano da Rocha, Sekine, Leo, Portich, Julia Plentz, Bosi, Guilherme Rasia, Calvache, Ebellins Tabares, Hoffmann, Daniel Sander   +7 more
core   +3 more sources

Molecular Study of Occult Hepatitis C Infection among Iranian Hemophilia Patients Treated with Direct-acting Antiviral Agents

Journal of Medical Microbiology and Infectious Diseases, 2020
Introduction: A new pathological form of HCV named as occult HCV infection (OCI) has been recently characterized by the presence of HCV RNA in liver biopsy and/or peripheral blood mononuclear cell specimens (PBMCs) and the absence of detectable ...
Elnaz Agi, Saber Asghari, Ali Namvar, Niloofar Khairkhah, Niloofar Naderi, Ali Anvar, Alireza Azizi Saraji, Azam Bolhassani   +7 more
doaj  

Strategies for Hemophilia Treatment, a literature review of current evidence

مجله دانشگاه علوم پزشکی بیرجند, 2023
Hemophilia is an inherited bleeding disorder caused by malfunctioning or lacking blood coagulation factor VIII (hemophilia A) or IX (hemophilia B). Currently, the main treatments for these X-linked diseases are replacement therapy using periodic and ...
Fahimeh Ghasemi, Nafiseh Erfanian, Samira Karbasi, Alireza Zomorodipour   +3 more
doaj